Unicycive Therapeutics develops investigational treatments for kidney diseases, with news centered on its clinical-stage pipeline, regulatory communications, financial results, and investor presentations. Its lead program, oxylanthanum carbonate, is an oral phosphate binder being developed for hyperphosphatemia in chronic kidney disease patients on dialysis, and company updates frequently address NDA activity, chemistry, manufacturing and controls matters, and commercial-readiness planning.
Unicycive also reports developments for UNI-494, a drug candidate for conditions related to acute kidney injury, including its FDA orphan drug designation for prevention of delayed graft function in kidney transplant patients and completed Phase 1 safety work. Recurring announcements include business updates, conference participation, and capital or cash-position disclosures tied to advancing the kidney-disease portfolio.
Unicycive Therapeutics, a clinical-stage biotechnology firm focused on kidney disease treatments, disclosed its Q2 2021 financial results. The company raised $25 million from its recent IPO and plans to meet the FDA in Q4 2021 regarding its lead product Renazorb. R&D expenses increased to $0.5 million from $0.2 million year-over-year, and net loss rose to $1.1 million or $0.13 per share. The company is working on the investigational drug UNI-494 and expects significant milestones in the upcoming periods.